Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
The Lancet Oncology.
Times cited: 199
Small cell lung cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?.
Journal of Thoracic Oncology.
Times cited: 73
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1 -mutant lung cancer.
Times cited: 69
Comprehensive genomic characterization of squamous cell lung cancers.
Times cited: 2085